| Document and Entity Information | 6 Months Ended |
| Jun. 30, 2024 | |
| Document Type | 6-K |
| Entity Central Index Key | 0001534248 |
| Document Period End Date | Jun. 30, 2024 |
| Current Fiscal Year End Date | --12-31 |
| Document Fiscal Year Focus | 2024 |
| Document Fiscal Period Focus | Q2 |
| Amendment Flag | false |
| Entity File Number | 001-38807 |
| Entity Registrant Name | CHEMOMAB THERAPEUTICS LTD. |
| Entity Address, Address Line One | Kiryat Atidim |
| Entity Address, Address Line Two | Building 7 |
| Entity Address, City or Town | Tel-Aviv |
| Entity Address, Country | IL |
| Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | |||
| Current assets | ||||||
| Cash and cash equivalents | $ 5,036 | $ 9,292 | ||||
| Short term bank deposits | 7,691 | 10,492 | ||||
| Restricted cash | 74 | 76 | ||||
| Other receivables and prepaid expenses | 654 | 1,037 | ||||
| Total current assets | 13,455 | 20,897 | ||||
| Non-current assets | ||||||
| Long term prepaid expenses | 472 | 559 | ||||
| Property and equipment, net | 276 | 303 | ||||
| Operating lease right-of-use assets | 341 | 392 | ||||
| Total non-current assets | 1,089 | 1,254 | ||||
| Total assets | 14,544 | 22,151 | ||||
| Current liabilities | ||||||
| Trade payables | 1,113 | 516 | ||||
| Accrued expenses | 2,546 | 3,423 | ||||
| Employee and related expenses | 540 | 823 | ||||
| Operating lease liabilities | 109 | 76 | ||||
| Total current liabilities | 4,308 | 4,838 | ||||
| Non-current liabilities | ||||||
| Operating lease liabilities - long term | 251 | 316 | ||||
| Total non-current liabilities | 251 | 316 | ||||
| Commitments and contingent liabilities | ||||||
| Total liabilities | 4,559 | 5,154 | ||||
| Shareholders' equity | ||||||
| Ordinary shares no par value - Authorized: 4,650,000,000 shares as of June 30, 2024 and 650,000,000 shares as of December 31, 2023; Issued and outstanding: 287,183,800 Ordinary shares as of June 30, 2024 and 284,094,700 as of December 31, 2023; | [1] | 0 | 0 | |||
| Additional paid in capital | [1] | 106,162 | 105,675 | |||
| Accumulated deficit | [1] | (96,177) | (88,678) | |||
| Total shareholders' equity | 9,985 | [1] | 16,997 | [1] | $ 21,991 | |
| Total liabilities and shareholders' equity | $ 14,544 | $ 22,151 | ||||
| [1]1 American Depositary Share (ADS) represents 20 Ordinary Shares | ||||||
| Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Jun. 30, 2024 | Dec. 31, 2023 | ||
| Statement of Financial Position [Abstract] | ||||
| Common Stock, No Par Value | $ 0 | [1] | $ 0 | |
| Common Stock, Shares Authorized | [1] | 4,650,000,000 | 650,000,000 | |
| Common Stock, Shares, Issued | [1] | 287,183,800 | 284,094,700 | |
| Common Stock, Shares, Outstanding | 287,183,800 | 284,094,700 | ||
| [1]1 American Depositary Share (ADS) represents 20 Ordinary Shares | ||||
| Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
| Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | ||
| Operating expenses | |||||
| Research and development | $ 2,928 | $ 5,020 | $ 6,080 | $ 11,907 | |
| General and administrative | 840 | 3,175 | 1,736 | 5,337 | |
| Total operating expenses | 3,768 | 8,195 | 7,816 | 17,244 | |
| Financing income, net | 137 | 259 | 317 | 576 | |
| Loss before taxes | 3,631 | 7,936 | 7,499 | 16,668 | |
| Taxes on income | 0 | 34 | 0 | 55 | |
| Net loss for the period | $ 3,631 | $ 7,970 | $ 7,499 | $ 16,723 | |
| Basic loss per Ordinary Share | [1] | $ 0.013 | $ 0.036 | $ 0.026 | $ 0.076 |
| Diluted loss per Ordinary Share | $ 0.013 | $ 0.036 | $ 0.026 | $ 0.076 | |
| Weighted average number of Ordinary Shares outstanding, basic | [1] | 286,080,133 | 221,674,130 | 285,111,876 | 221,338,951 |
| Weighted average number of Ordinary Shares outstanding, diluted | 286,080,133 | 221,674,130 | 285,111,876 | 221,338,951 | |
| [1]1 American Depositary Share (ADS) represents 20 Ordinary Shares | |||||
| Interim Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands | Ordinary Shares [Member] | Treasury share [Member] | Additional paid in capital [Member] | Accumulated Deficit [Member] | Total | |||
| Beginning balance at Dec. 31, 2022 | $ 0 | [1],[2] | $ (1,218) | $ 101,260 | $ (63,819) | $ 36,223 | ||
| Beginning balance (In shares) at Dec. 31, 2022 | 232,636,700 | [1],[2] | (11,640,460) | |||||
| Share-based compensation | $ 0 | [1],[2] | $ 0 | 484 | 0 | 484 | ||
| Net loss for the period | 0 | [1],[2] | 0 | 0 | (8,753) | (8,753) | ||
| Ending balance at Mar. 31, 2023 | $ 0 | [1],[2] | $ (1,218) | 101,744 | (72,572) | 27,954 | ||
| Ending balance (in shares) at Mar. 31, 2023 | 232,636,700 | [1],[2] | (11,640,460) | |||||
| Beginning balance at Dec. 31, 2022 | $ 0 | [1],[2] | $ (1,218) | 101,260 | (63,819) | 36,223 | ||
| Beginning balance (In shares) at Dec. 31, 2022 | 232,636,700 | [1],[2] | (11,640,460) | |||||
| Net loss for the period | (16,723) | |||||||
| Ending balance at Jun. 30, 2023 | $ 0 | [1],[2] | $ (1,218) | 103,751 | (80,542) | 21,991 | ||
| Ending balance (in shares) at Jun. 30, 2023 | 248,058,700 | [1],[2] | (11,640,460) | |||||
| Beginning balance at Mar. 31, 2023 | $ 0 | [1],[2] | $ (1,218) | 101,744 | (72,572) | 27,954 | ||
| Beginning balance (In shares) at Mar. 31, 2023 | 232,636,700 | [1],[2] | (11,640,460) | |||||
| Share-based compensation | $ 0 | [1],[2] | $ 0 | 639 | 0 | 639 | ||
| Issuance of shares (in shares) | [1],[2] | 15,422,000 | ||||||
| Issuance of shares | $ 0 | [1],[2] | 0 | 1,368 | 0 | 1,368 | ||
| Net loss for the period | 0 | [1],[2] | 0 | 0 | (7,970) | (7,970) | ||
| Ending balance at Jun. 30, 2023 | $ 0 | [1],[2] | $ (1,218) | 103,751 | (80,542) | 21,991 | ||
| Ending balance (in shares) at Jun. 30, 2023 | 248,058,700 | [1],[2] | (11,640,460) | |||||
| Beginning balance at Dec. 31, 2023 | $ 0 | [1],[2] | 105,675 | (88,678) | 16,997 | [1] | ||
| Beginning balance (In shares) at Dec. 31, 2023 | [1],[2] | 284,094,700 | ||||||
| Share-based compensation | $ 0 | [1],[2] | 191 | 0 | 191 | |||
| Issuance of shares (in shares) | [1],[2] | 285,260 | ||||||
| Issuance of shares | $ 0 | [1],[2] | 11 | 0 | 11 | |||
| Net loss for the period | 0 | [1],[2] | 0 | (3,868) | (3,868) | |||
| Ending balance at Mar. 31, 2024 | $ 0 | [1],[2] | 105,877 | (92,546) | 13,331 | |||
| Ending balance (in shares) at Mar. 31, 2024 | [1],[2] | 284,379,960 | ||||||
| Beginning balance at Dec. 31, 2023 | $ 0 | [1],[2] | 105,675 | (88,678) | 16,997 | [1] | ||
| Beginning balance (In shares) at Dec. 31, 2023 | [1],[2] | 284,094,700 | ||||||
| Net loss for the period | (7,499) | |||||||
| Ending balance at Jun. 30, 2024 | $ 0 | [1],[2] | 106,162 | (96,177) | 9,985 | [1] | ||
| Ending balance (in shares) at Jun. 30, 2024 | [1],[2] | 287,183,800 | ||||||
| Beginning balance at Mar. 31, 2024 | $ 0 | [1],[2] | 105,877 | (92,546) | 13,331 | |||
| Beginning balance (In shares) at Mar. 31, 2024 | [1],[2] | 284,379,960 | ||||||
| Share-based compensation | $ 0 | [1],[2] | 164 | 0 | 164 | |||
| Issuance of shares (in shares) | [1],[2] | 2,803,840 | ||||||
| Issuance of shares | $ 0 | [1],[2] | 121 | 0 | 121 | |||
| Net loss for the period | 0 | [1],[2] | 0 | (3,631) | (3,631) | |||
| Ending balance at Jun. 30, 2024 | $ 0 | [1],[2] | $ 106,162 | $ (96,177) | $ 9,985 | [1] | ||
| Ending balance (in shares) at Jun. 30, 2024 | [1],[2] | 287,183,800 | ||||||
| [1]1 American Depositary Share (ADS) represents 20 Ordinary Shares[2]Ordinary shares no par value | ||||||||
| Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
| Jun. 30, 2024 | Jun. 30, 2023 | |
| Cash flows from operating activities | ||
| Net loss for the period | $ (7,499) | $ (16,723) |
| Adjustments for operating activities: | ||
| Depreciation | 27 | 32 |
| Share-based compensation | 355 | 1,123 |
| Change in other receivables and prepaid expenses (short and long term) | 470 | 811 |
| Change in operating leases | 19 | (6) |
| Change in trade payables | 597 | 659 |
| Change in accrued expenses | (877) | (875) |
| Change in employees and related expenses | (283) | 307 |
| Adjustments for operating activities | 308 | 2,051 |
| Net cash used in operating activities | (7,191) | (14,672) |
| Cash flows from investing activities | ||
| Decrease in bank deposits | 2,801 | 10,167 |
| Purchase of property and equipment | 0 | (3) |
| Net cash provided by investing activities | 2,801 | 10,164 |
| Cash flows from financing activities | ||
| Issuance of Shares, net of issuance expenses | 132 | 1,368 |
| Net cash provided by financing activities | 132 | 1,368 |
| Decrease in cash, cash equivalents and restricted cash | (4,258) | (3,140) |
| Cash, cash equivalents and restricted cash at beginning of period | 9,368 | 13,596 |
| Cash, cash equivalents and restricted cash at end of period | $ 5,110 | $ 10,456 |
| General | 6 Months Ended |
| Jun. 30, 2024 | |
| Nature Of Operations Disclosure [Abstract] | |
| General | Note 1 - General A. Chemomab Therapeutics Ltd. (the “Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company’s registered office is located in Kiryat Atidim, Tel Aviv, Israel. The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis. The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc. The Company currently has no products approved for sale. The Company’s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company’s development programs depend on its future ability to raise sources of financing. The Company believes that following the fundraising closed on July 2024, its existing liquidity resources will enable it to fund its operations through the beginning of 2026 with the ability to perform cost reductions in order to extend the operations even further, if required to do so. B. In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (“Roth”). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $2,863,664 through Roth or the Roth ATM Agreement. From October 30, 2023, through June 30, 2024, the Company issued 1,954,455 ADSs at an average price of approximately $0.95 per ADS under the Roth ATM Agreement, resulting in net proceeds of $1,674 thousand. |
| Basis of Presentation and Significant Accounting Policies | 6 Months Ended |
| Jun. 30, 2024 | |
| Accounting Policies [Abstract] | |
| Basis of Presentation and Significant Accounting Policies | Note 2 - Basis of Presentation and Significant Accounting Policies A. Basis of Preparation The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of June 30, 2024, and its results of operations for the six and three months ended June 30, 2024, and 2023, changes in shareholders’ equity for the six and three months ended June 30, 2024 and 2023, and cash flows for the six and three months ended June 30, 2024 and 2023. The results of operations for the six and three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 20-F. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. B. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. |
| Contingencies | 6 Months Ended |
| Jun. 30, 2024 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| Contingencies | Note 3 - Contingencies During 2022, the Israeli tax authority ("ITA”) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2022. The ITA raised several claims, mainly in respect with the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. In July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. In November 2022, the Company filed an appeal to the ITA’s assessment. The Company has recorded a provision in 2022 that is inherently subjective due to the inherent uncertainty of these matters and the judicial process, therefore, the outcome may differ from the estimated liability recorded by the Company during 2022. In October 2023 the ITA rejected the Company’s appeal on the assessment. The Company filed an appeal to the Israeli district court. Based on the consultancy of its tax advisors, the Company estimates that the amount of provision recorded in 2022 remains adequate. |
| Subsequent events | 6 Months Ended |
| Jun. 30, 2024 | |
| Subsequent Events [Abstract] | |
| Subsequent events | Note 4 - Subsequent events On July 25, 2024, the Company entered into Securities Purchase Agreements with existing and new investors of the Company (the "Purchasers"), pursuant to which the Company agreed to sell $10.0 million of its ADSs in a private placement transaction, (or "The Private Placement"). The Private Placement closed on July 30, 2024, at which time the Company sold to the Purchasers 4,148,867 ADSs together with pre-funded warrants to purchase up to 3,948,300 ADSs at an exercise price of $0.0001 per ADS. The Private Placement did not include any warrant coverage or other dilutive terms. |
| Basis of Presentation and Significant Accounting Policies (Policies) | 6 Months Ended |
| Jun. 30, 2024 | |
| Accounting Policies [Abstract] | |
| Basis of Preparation | A. Basis of Preparation The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of June 30, 2024, and its results of operations for the six and three months ended June 30, 2024, and 2023, changes in shareholders’ equity for the six and three months ended June 30, 2024 and 2023, and cash flows for the six and three months ended June 30, 2024 and 2023. The results of operations for the six and three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 20-F. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. |
| Use of estimates | B. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. |
| General (Detail Textuals) - American Depositary Share ("ADS") [Member] - At The Market Offering Agreement With Cantor Fitzgerald & Co. [Member] | 6 Months Ended |
| Jun. 30, 2024 USD ($) $ / shares shares | |
| Restructuring Cost and Reserve [Line Items] | |
| Aggregate offering price | $ 2,863,664 |
| Shares issued under agreement | shares | 1,954,455 |
| Average price of shares issued | $ / shares | $ 0.95 |
| Gross proceeds from sale under agreement | $ 1,674,000 |
| Subsequent events (Detail Textuals) - Subsequent Event [Member] - Private Placement [Member] $ / shares in Units, $ in Millions | 1 Months Ended |
| Jul. 25, 2024 USD ($) $ / shares shares | |
| Subsequent Event [Line Items] | |
| Proceeds from sale of ADS | $ | $ 10 |
| ADS and pre-funded warrants sold to the Purchasers | 4,148,867 |
| ADS issued against pre-funded warrants | 3,948,300 |
| ADS, exercise price | $ / shares | $ 0.0001 |
